Ignite Creation Date:
2024-05-06 @ 3:49 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04774380
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-13
First Post:
2021-02-25
Brief Title:
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-11-11
Start Date Type:
ACTUAL
Primary Completion Date:
2023-06-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-25
First Submit QC Date:
February 25 2021
Study First Post Date:
2021-03-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-17
Last Update Post Date:
2024-05-13
Last Update Post Date Type:
ACTUAL